Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05538247 · ClinicalTrials.gov registry record · Early Phase 1
Saccharomyces Boulardii CNCM I-745 on Intestinal Barrier Function
A Early Phase 1 study of Healthy, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 56
- Enrollment target
- 1
- Study location
NCT05538247 is a Early Phase 1 study of Healthy that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 56 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05538247, a Early Phase 1 study of Healthy, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 56 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is being done to assess the effects of S. boulardii CNCM I-745 compared to placebo on impaired intestinal permeability, which is the control of material passing from inside the gastrointestinal tract through the cells lining the gut wall into the rest of the body.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Indomethacin
- DIETARY_SUPPLEMENT S. boulardii CNCM I-745
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2023-04-13 |
| Est. Completion | 2026-03-31 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05538247
The ClinicalTrials.gov registry entry for NCT05538247 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (91% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT05538247 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT05538247 about?
NCT05538247 is a clinical study titled "Saccharomyces Boulardii CNCM I-745 on Intestinal Barrier Function". This study is being done to assess the effects of S. boulardii CNCM I-745 compared to placebo on impaired intestinal permeability, which is the control of material passing from inside the gastrointestinal tract through the cells lining the gut wall into the rest of the body.
What is the current status of trial NCT05538247?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 56 participants. The study started on 2023-04-13. Estimated completion is 2026-03-31.
What conditions does trial NCT05538247 study?
This clinical trial studies the following conditions: Healthy.
What interventions are being tested in trial NCT05538247?
The interventions under investigation include: Placebo (DRUG), Indomethacin (DRUG), S. boulardii CNCM I-745 (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT05538247?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05538247 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Mapping Auricular Vagus Nerve Circuitry
RECRUITING · Early Phase 1
-
SV2A Density Cannabis Use Disorder
RECRUITING · Early Phase 1
-
CBD-Microglia PET Study
RECRUITING · Early Phase 1
-
Sex Disparities in Hypoxic Vasodilation and Impact of Obesity
RECRUITING · Early Phase 1
-
Positron Emission Tomography (PET) Contrast Agent Kinetics and Safety: [18F]-Fluoromannitol
RECRUITING · Early Phase 1
-
Study to Assess the Safety, Tolerability, PK and PD of ABX1100
ACTIVE NOT RECRUITING · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.